01 / IDENTITY
Compound Profile
GLP-1R AGONIST
Insulin secretion · Appetite suppression · Gastric emptying · Cardioprotection
GIPR AGONIST
Enhanced insulin secretion · Adipose tissue remodeling · Central satiety · Lean mass preservation
GCGR
Not activated (see Retatrutide for triple agonist)
ORIGIN
Developed by Eli Lilly. Single synthetic peptide that activates both GLP-1R and GIPR with balanced affinity. Approved as Mounjaro (diabetes, 2022) and Zepbound (obesity, 2023). First dual incretin receptor agonist approved by FDA.
WHY DUAL AGONISM WINS
GIP (glucose-dependent insulinotropic polypeptide) works synergistically with GLP-1 in the pancreas and brain. Together: stronger insulin response, more potent appetite suppression, and GIPR activation in adipose tissue remodels fat distribution and may preserve muscle mass — an advantage vs. GLP-1 monotherapy.
HEAD-TO-HEAD VS SEMAGLUTIDE
SURMOUNT-5 trial (2025): tirzepatide 15mg produces 20.2% weight loss vs. 13.7% for semaglutide 2.4mg — a 47% superior result. Tirzepatide has consistently outperformed semaglutide in every head-to-head measure across HbA1c, weight loss, and cardiometabolic markers.
LEAN MASS ADVANTAGE
GIPR activation appears to preserve lean muscle mass during weight loss vs. GLP-1 monotherapy. Body composition data shows higher percentage of fat vs. lean mass lost with tirzepatide — clinically significant for maintaining metabolic rate and functional capacity.
02 / RESEARCH HISTORY
Development Timeline
2000s
Eli Lilly researchers explore the incretin axis beyond GLP-1. GIP identified as a second major incretin hormone with distinct receptor (GIPR) expressed in adipose tissue, brain, and pancreas. Hypothesis: dual activation may be synergistic.
2017–2019
Phase I/II trials establish safety and dose-response. GIPR co-activation shows unexpected enhancement of GLP-1R effects in the brain and pancreas — dual agonism produces non-additive (synergistic) results in appetite and insulin secretion.
2021
SURPASS trial series published: tirzepatide 15mg achieves 2.0–2.4% HbA1c reduction and 11–15% weight loss in T2DM. Outperforms semaglutide 1mg in SURPASS-2.
2022–2023
FDA approves Mounjaro (T2DM, 2022) and Zepbound (obesity, 2023). SURMOUNT-1: 22.5% weight loss at 72 weeks in non-diabetic obese adults — the largest weight loss ever recorded in a clinical trial for a pharmaceutical agent.
2025
SURMOUNT-5 head-to-head trial: tirzepatide 20.2% vs. semaglutide 13.7% weight loss. SURPASS-CVOT ongoing. GIPR mechanism in lean mass preservation increasingly studied. Compounding pharmacy versions emerge following shortage designations.
03 / BENEFITS & MECHANISMS
Research-Supported Effects
WEIGHT LOSS
22.5%
Mean at 15mg × 72 weeks (SURMOUNT-1). Best result of any drug in obesity trial history.
HbA1c REDUCTION
2.4%
At 15mg in T2DM patients. 40% of patients achieved near-normal HbA1c (<5.7%).
LEAN MASS RETENTION
Better
GIPR activation in adipose tissue preferentially reduces fat mass over lean mass vs. GLP-1 alone.
01
Superior Weight Loss vs. Any Prior Drug
SURMOUNT-1 (2022): 22.5% mean body weight reduction at tirzepatide 15mg × 72 weeks. 1 in 3 patients lost ≥25% of body weight. 57% of patients at 15mg achieved <5% body weight — clinically defined as successful weight loss treatment. No pharmaceutical has produced these results before tirzepatide.
02
Dual Incretin Synergy — More Than Additive
GLP-1R + GIPR co-activation at the hypothalamic level produces appetite suppression exceeding either receptor alone. GIPR in the arcuate nucleus amplifies GLP-1R satiety signaling — explaining why tirzepatide produces greater food intake reduction than equimolar semaglutide. The combination is synergistic, not merely additive.
03
Adipose Tissue Remodeling
GIPR is highly expressed in adipocytes (fat cells). Tirzepatide's GIPR activation directly remodels adipose tissue — reducing adipocyte size, improving insulin sensitivity in fat tissue, and shifting fat distribution away from visceral depots. This mechanism is completely absent from GLP-1 monotherapy drugs.
04
Sleep Apnea Resolution
SURMOUNT-OSA trial (2024): 63–79% reduction in apnea-hypopnea index (AHI) with tirzepatide. 42% of patients with moderate-severe OSA achieved complete remission. The degree of sleep apnea improvement was directly correlated with weight loss — the most impactful trial for OSA short of CPAP therapy.
05
Heart Failure Improvement
SUMMIT trial (2024): tirzepatide significantly improved exercise capacity (6-minute walk test), quality of life, and reduced heart failure-related hospitalization in HFpEF (heart failure with preserved ejection fraction). GLP-1R expression in cardiac tissue + weight reduction + reduced inflammation are all contributing mechanisms.
04 / RECONSTITUTION
Vial Preparation
COMPOUNDED TIRZEPATIDE — TYPICAL VIALS: 5mg, 10mg, 15mg
Standard: 10mg vial + 2.0 mL (200 units) bacteriostatic water
Concentration: 0.05 mg per unit (50 mcg per unit)
| DOSE | mg | UNITS ON SYRINGE | VOLUME |
|---|
| STARTING |
2.5mg |
50 units |
0.50 mL |
| STEP 2 |
5.0mg |
100 units |
1.0 mL |
| STEP 3 |
7.5mg |
150 units |
1.5 mL |
| STEP 4 |
10.0mg |
200 units |
2.0 mL |
| TARGET MAX |
15.0mg |
Requires 15mg vial at appropriate concentration |
Per provider label |
⚠ Confirm Concentration on Every Vial: Compounded tirzepatide vial concentrations vary by pharmacy (common: 2.5mg/mL, 5mg/mL, 10mg/mL). Always verify the mg/mL concentration printed on your pharmacy label. Recalculate units for each new vial.
Storage: Refrigerate (2–8°C). After reconstitution, use within 28 days. Protect from light. Do NOT freeze. Once-weekly injection — one vial covers several weeks of escalation dosing.
05 / DOSE ESCALATION PROTOCOL
Standard Escalation — Every 4 Weeks
| WEEKS | DOSE | FREQUENCY | CLINICAL NOTE |
|---|
| 1–4 | 2.5 mg | Once weekly SC | Tolerability phase. Mild nausea expected. Do not skip or reduce — adaptation requires exposure. |
| 5–8 | 5.0 mg | Once weekly SC | First meaningful weight loss signal. Appetite noticeably suppressed. GI effects improving. |
| 9–12 | 7.5 mg | Once weekly SC | Weight loss accelerating. Blood glucose improving in T2DM patients. HbA1c starting to shift. |
| 13–16 | 10.0 mg | Once weekly SC | Strong fat loss phase. Most patients report dramatic reduction in food noise. Visceral fat reduces. |
| 17–20 | 12.5 mg | Once weekly SC | Near-maximum dose. Significant body recomposition visible. Metabolic markers normalizing. |
| 21+ | 15.0 mg | Once weekly SC (maintenance) | Maximum dose — SURMOUNT results achieved at this dose. 22.5% mean weight loss over 72 weeks. |
Maintenance Flexibility: Many patients find significant results at 5–10mg and do not need to escalate to 15mg. Dose to effect — the goal is maximum tolerated dose that produces target weight loss and metabolic normalization, not necessarily the maximum possible dose.
06 / TIMING & ADMINISTRATION
Injection Protocol
FREQUENCY
Once Weekly — Same Day
TIMING
Any time of day — with or without food. Consistency of day matters more than time of day. Most patients choose AM on a fixed day (e.g., Sunday morning).
INJECTION SITES
Abdomen (preferred), outer thigh, upper arm. Rotate sites weekly. Avoid 2-inch radius around navel.
GI MANAGEMENT
More potent than semaglutide = slightly higher GI side effect profile. Same strategies apply: inject before bed, eat small low-fat meals injection day, avoid alcohol 24h. Nausea peaks 8–12h post-injection.
OPTIMAL COMPANION STACK
Tirzepatide + AOD-9604 500mcg AM (direct lipolysis) + MOTS-c 5mg AM (mitochondrial efficiency). For muscle preservation: add CJC/Ipamorelin blend bedtime to drive GH-mediated lean mass retention.
07 / BIOMARKER MONITORING
Recommended Lab Panel
METABOLIC — PRIMARY
| MARKER | CLINICAL RANGE | OPTIMAL TARGET | NOTES |
|---|
| HbA1chemoglobin A1c |
CLINICAL<5.7% |
OPTIMAL<5.3% |
Recheck at 12 weeks. 40% of diabetic patients achieve near-normal HbA1c at max dose. |
| Fasting Insulin + HOMA-IRinsulin resistance |
CLINICALHOMA-IR <2.5 |
OPTIMALHOMA-IR <1.5 |
GIPR activation in adipose tissue directly improves insulin sensitivity — track progressive improvement. |
| Adiponectinadipokine |
CLINICAL>5 µg/mL |
OPTIMAL>10 µg/mL |
GIPR-specific: tirzepatide elevates adiponectin (the "good" fat hormone) via direct adipose remodeling. Rising adiponectin = improved fat tissue function. Unique biomarker vs. GLP-1 monotherapy. |
| Lipid PanelTG, LDL, HDL |
CLINICALStandard |
OPTIMALTG <80 / LDL <70 |
TG improvement is particularly pronounced with tirzepatide vs. semaglutide due to GIPR adipose effects. |
BODY COMPOSITION
| METHOD | TIMING | NOTES |
|---|
| DEXA Scandual-energy X-ray absorptiometry |
Baseline → 16 weeks → 32 weeks |
Lean mass vs. fat mass tracking. Confirm GIPR lean mass preservation effect. If lean mass is declining, add resistance training + protein + GH secretagogue. |
08 / CYCLE PROTOCOL
Administration Schedule
DURATION
Ongoing Maintenance Therapy
LONG-TERM EVIDENCE
SURMOUNT-4 extension: continued weight maintenance with ongoing therapy. Discontinuation leads to weight regain (~14% in 1 year off-drug). Current medical consensus: chronic therapy required for sustained benefit, similar to hypertension medication.
TIRZEPATIDE vs. SEMAGLUTIDE — CHOOSING
Tirzepatide: superior weight loss, better lean mass outcomes, better TG reduction, higher cost. Semaglutide: longer safety record (6 years vs. 3), confirmed MACE benefit data, widely compounded. Patient factors: weight loss goal, metabolic profile, cost, and provider preference drive the choice.
REQUIRES
BAC water for reconstitution · Apex V3 Pen for precise weekly dosing · Refrigeration · Provider prescription for compounded access
⚠ Research reference only. Compounded tirzepatide regulatory status differs from FDA-approved Mounjaro/Zepbound. Consult a licensed prescriber. Data sourced from SURPASS, SURMOUNT, SUMMIT, and SURMOUNT-OSA trial series.